Published in J Alzheimers Dis on February 01, 2005
Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI) (POEM) | NCT00736996
Clinical Effects of Pulsatile Insulin Delivery on Cognitive Function- Phase 1 | NCT00228865
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest (2012) 3.65
Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron (2008) 2.99
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest (2012) 2.33
Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 1.97
Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition (2010) 1.89
Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol (2012) 1.89
Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci (2009) 1.88
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci (2008) 1.81
Pancreatic function, type 2 diabetes, and metabolism in aging. Int J Endocrinol (2012) 1.77
Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol Learn Mem (2010) 1.70
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis (2009) 1.53
Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res (2008) 1.50
Insulin resistance and Alzheimer's disease. BMB Rep (2009) 1.49
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol Biol Cell (2009) 1.45
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis (2010) 1.36
Insulin in central nervous system: more than just a peripheral hormone. J Aging Res (2012) 1.33
Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs (2013) 1.30
Insulin receptor signaling in the development of neuronal structure and function. Neural Dev (2010) 1.29
Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol (2011) 1.29
Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med (2010) 1.28
Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem (2007) 1.25
NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol Neurodegener (2010) 1.23
Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J Neurochem (2008) 1.23
Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc Natl Acad Sci U S A (2008) 1.23
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol (2011) 1.22
Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21
Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21
Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol (2013) 1.21
Insulin action in brain regulates systemic metabolism and brain function. Diabetes (2014) 1.18
Low density lipoprotein receptor-related protein 1 promotes anti-apoptotic signaling in neurons by activating Akt survival pathway. J Biol Chem (2009) 1.16
Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis (2009) 1.15
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol (2009) 1.14
Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol (2011) 1.12
Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest (2013) 1.12
Identification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression. Neuroimage (2012) 1.10
Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol (2012) 1.10
Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study. Cereb Cortex (2013) 1.09
Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. PLoS One (2012) 1.09
Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis (2009) 1.07
Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? Am J Cardiovasc Dis (2013) 1.05
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs (2012) 1.05
Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J (2012) 1.04
Interactions between age, stress and insulin on cognition: implications for Alzheimer's disease. Neuropsychopharmacology (2010) 1.04
Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev (2011) 1.03
Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. Biochim Biophys Acta (2011) 1.03
Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem (2009) 1.03
Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol Dis (2008) 1.02
Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem (2011) 1.02
Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes (2014) 1.01
Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta (2014) 1.01
The cycad genotoxin MAM modulates brain cellular pathways involved in neurodegenerative disease and cancer in a DNA damage-linked manner. PLoS One (2011) 1.01
O-GlcNAc cycling mutants modulate proteotoxicity in Caenorhabditis elegans models of human neurodegenerative diseases. Proc Natl Acad Sci U S A (2012) 1.00
Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway. J Biol Chem (2012) 1.00
Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol (Lausanne) (2014) 0.98
Hippocampal insulin resistance and cognitive dysfunction. Nat Rev Neurosci (2015) 0.97
Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathol (2014) 0.97
Food for thought: the role of appetitive peptides in age-related cognitive decline. Ageing Res Rev (2013) 0.97
Neurodegeneration: Recall sugars, forget Alzheimer's. Nat Chem Biol (2012) 0.97
Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system. Brain Struct Funct (2009) 0.97
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna) (2012) 0.97
Intersection between metabolic dysfunction, high fat diet consumption, and brain aging. J Neurochem (2010) 0.96
Effect of high-fat diet on metabolic indices, cognition, and neuronal physiology in aging F344 rats. Neurobiol Aging (2013) 0.95
Insulin receptor signaling mediates APP processing and β-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease. Age (Dordr) (2011) 0.95
Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurodegener (2009) 0.95
Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiol Aging (2013) 0.94
Insulin receptor substrate 2 is a negative regulator of memory formation. Learn Mem (2011) 0.94
Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin Exp Res (2008) 0.94
Central obesity in the elderly is related to late-onset Alzheimer disease. Alzheimer Dis Assoc Disord (2012) 0.94
Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis (2009) 0.94
Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. Front Neurosci (2015) 0.94
Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener (2010) 0.94
Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease. PLoS One (2012) 0.94
Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm (Vienna) (2011) 0.94
Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res (2010) 0.93
Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. Clin Interv Aging (2015) 0.93
Aberrant insulin signaling in Alzheimer's disease: current knowledge. Front Neurosci (2015) 0.92
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) (2012) 0.92
Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS One (2012) 0.92
The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. J Alzheimers Dis (2010) 0.92
Cerebral energy metabolism and the brain's functional network architecture: an integrative review. J Cereb Blood Flow Metab (2013) 0.92
Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 0.92
Is Alzheimer's disease a systemic disease? Biochim Biophys Acta (2014) 0.92
Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis (2012) 0.91
A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol (2012) 0.91
Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J Alzheimers Dis (2010) 0.91
Mitochondrial respiratory chain is involved in insulin-stimulated hydrogen peroxide production and plays an integral role in insulin receptor autophosphorylation in neurons. BMC Neurosci (2007) 0.91
Amyloid-β oligomers induce differential gene expression in adult human brain slices. J Biol Chem (2012) 0.91
Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2009) 0.91
Insulin/PI3K signaling protects dentate neurons from oxygen-glucose deprivation in organotypic slice cultures. J Neurochem (2009) 0.91
Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. Diabetes (2012) 0.90
Insulin signaling in sporadic Alzheimer's disease. Sci Signal (2009) 0.90
Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. Aging Dis (2015) 0.90
Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review. Eur Neuropsychopharmacol (2014) 0.90
Effects of long-term pioglitazone treatment on peripheral and central markers of aging. PLoS One (2010) 0.90
Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence? J Exp Med (2016) 0.89
Amyloid-β induces hepatic insulin resistance in vivo via JAK2. Diabetes (2012) 0.89
Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med (2008) 4.57
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab (2010) 2.40
Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 2.12
Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis (2005) 2.11
Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 1.97
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2006) 1.82
Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol (2003) 1.80
Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res (2010) 1.77
The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res (2008) 1.71
Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimers Dis (2003) 1.69
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis (2006) 1.65
Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes (2010) 1.64
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology (2006) 1.64
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56
Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci (2006) 1.50
Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology (2006) 1.49
Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis (2006) 1.48
Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology (2006) 1.44
Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol (2013) 1.40
Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res (2004) 1.37
Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol (2005) 1.33
Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer (2003) 1.32
Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun (2010) 1.31
Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology (2007) 1.31
The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res (2004) 1.30
Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology (2005) 1.30
Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol (2008) 1.28
Prevention of hepatocellular carcinoma. N Engl J Med (2004) 1.27
Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology (2003) 1.26
Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis (2008) 1.26
Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology (2004) 1.24
Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res (2007) 1.23
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol (2006) 1.22
Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res (2008) 1.22
Mitochondrial transporter ATP binding cassette mitochondrial erythroid is a novel gene required for cardiac recovery after ischemia/reperfusion. Circulation (2011) 1.22
Alcohol-induced disruption of endocrine signaling. Alcohol Clin Exp Res (2007) 1.21
Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21
PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol (2009) 1.20
Acute and chronic alcohol abuse modulate immunity. Alcohol Clin Exp Res (2006) 1.18
Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev (2010) 1.18
Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol (2012) 1.16
Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis (2009) 1.15
Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol (2004) 1.13
Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest (2002) 1.12
Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? Cell Cycle (2011) 1.10
Hepatitis C virus and alcohol. Semin Liver Dis (2009) 1.08
Chronic ethanol exposure causes mitochondrial dysfunction and oxidative stress in immature central nervous system neurons. Acta Neuropathol (2007) 1.08
Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology (2006) 1.07
Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease. Oxid Med Cell Longev (2012) 1.07
Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis (2009) 1.07
Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J Hepatol (2010) 1.07
Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl-beta-hydroxylase expression. Acta Neuropathol (2008) 1.06
Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology (2003) 1.06
Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology (2006) 1.04
Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biol (2006) 1.04
Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration. Alcohol (2009) 1.04
Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology (2003) 1.03
Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol (2010) 1.02
Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev (2004) 1.01
Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology (2009) 1.01
Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology (2002) 1.01
The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health (2009) 1.00
Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. J Hepatol (2010) 0.99
Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation: Relevance to early pregnancy loss. Hum Pathol (2006) 0.99
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res (2010) 0.98
Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res (2011) 0.98
Ethanol-induced oxidative stress and mitochondrial dysfunction in rat placenta: relevance to pregnancy loss. Alcohol Clin Exp Res (2009) 0.97
Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One (2012) 0.97
Uncoupling protein-2 modulates the lipid metabolic response to fasting in mice. Am J Physiol Gastrointest Liver Physiol (2008) 0.96
The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. Biochem Biophys Res Commun (2010) 0.96
Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol (2012) 0.96
Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol (2010) 0.94
Aspartyl-(asparaginyl) beta-hydroxylase, hypoxia-inducible factor-alpha and Notch cross-talk in regulating neuronal motility. Oxid Med Cell Longev (2010) 0.94
Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance. Gastroenterol Res Pract (2010) 0.94
ATP luminescence-based motility-invasion assay. Biotechniques (2002) 0.94
Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin Exp Res (2008) 0.94
Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. Carcinogenesis (2006) 0.94
Presence of antibodies against genogroup VI norovirus in humans. Virol J (2013) 0.94